|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
|
US4853228A
(en)
|
1987-07-28 |
1989-08-01 |
Micro-Pak, Inc. |
Method of manufacturing unilamellar lipid vesicles
|
|
DK0737750T3
(da)
|
1989-03-21 |
2003-09-01 |
Vical Inc |
Ekspression af exogene polynucleotidsekvenser i vertebrater
|
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
US5750390A
(en)
|
1992-08-26 |
1998-05-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
|
|
US5693535A
(en)
|
1992-05-14 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
HIV targeted ribozymes
|
|
WO1993025673A1
(en)
|
1992-06-04 |
1993-12-23 |
The Regents Of The University Of California |
In vivo gene therapy with intron-free sequence of interest
|
|
EP1251170A3
(en)
|
1992-07-17 |
2002-10-30 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of NF-kappaB dependent animal diseases
|
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
|
US20020102273A1
(en)
|
1995-08-08 |
2002-08-01 |
Robert B. Grieve |
Use of alphavirus expression vectors to produce parasite anitgens
|
|
JPH09500013A
(ja)
|
1993-06-01 |
1997-01-07 |
ライフ・テクノロジーズ・インコーポレイテッド |
カチオン性脂質による遺伝子免疫
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
WO1995027721A1
(en)
|
1994-04-07 |
1995-10-19 |
Akzo Nobel N.V. |
Freeze-dried compositions comprising rna
|
|
US5993850A
(en)
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
JPH11512609A
(ja)
|
1995-09-27 |
1999-11-02 |
アメリカ合衆国 |
クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
|
|
CA2244110A1
(en)
|
1996-02-12 |
1997-08-14 |
Cobra Therapeutics Limited |
Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
|
|
DE19605548A1
(de)
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
CA2259179C
(en)
|
1996-07-03 |
2008-09-23 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
|
CN1138533C
(zh)
|
1996-09-13 |
2004-02-18 |
利普森有限公司 |
脂质体
|
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
AU733310C
(en)
|
1997-05-14 |
2001-11-29 |
University Of British Columbia, The |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
US6048546A
(en)
|
1997-07-31 |
2000-04-11 |
Sandia Corporation |
Immobilized lipid-bilayer materials
|
|
US6060308A
(en)
|
1997-09-04 |
2000-05-09 |
Connaught Laboratories Limited |
RNA respiratory syncytial virus vaccines
|
|
JP2002500003A
(ja)
*
|
1997-11-28 |
2002-01-08 |
ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス |
フラビウイルスの発現および送達のシステム
|
|
US6009406A
(en)
|
1997-12-05 |
1999-12-28 |
Square D Company |
Methodology and computer-based tools for re-engineering a custom-engineered product line
|
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
EP2311436A1
(en)
*
|
1998-04-27 |
2011-04-20 |
Altus Pharmaceuticals Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
|
CA2336554A1
(en)
|
1998-06-29 |
2000-01-06 |
U.S. Medical Research Institute Of Infectious Diseases |
Marburg virus vaccines
|
|
WO2000003683A2
(en)
|
1998-07-20 |
2000-01-27 |
Inex Pharmaceuticals Corporation |
Liposomal encapsulated nucleic acid-complexes
|
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
GB9908309D0
(en)
|
1999-04-12 |
1999-06-02 |
Phares Pharm Res Nv |
Lipid aggregate forming compositions and their use
|
|
EP1541690A3
(en)
|
1999-09-09 |
2005-07-27 |
CureVac GmbH |
Transfer of mRNA using polycationic compounds
|
|
CA2388045C
(en)
|
1999-10-20 |
2014-02-11 |
Tzyy-Choou Wu |
Nucleic acid immunogenic compositions encoding hsp-antigen chimera
|
|
US8541008B2
(en)
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
|
US20030212022A1
(en)
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
|
US7149665B2
(en)
|
2000-04-03 |
2006-12-12 |
Browzwear International Ltd |
System and method for simulation of virtual wear articles on virtual models
|
|
CA2403508A1
(en)
|
2000-04-18 |
2001-10-25 |
Human Genome Sciences, Inc. |
Extracellular matrix polynucleotides, polypeptides, and antibodies
|
|
MXPA02012198A
(es)
|
2000-06-09 |
2004-08-19 |
Teni Boulikas |
Encapsulacion de polinucleotidos y drogas en liposomas objetivos.
|
|
CA2414884A1
(en)
|
2000-07-03 |
2002-01-10 |
Chiron S.P.A. |
Immunisation against chlamydia pneumoniae
|
|
AU2001290520A1
(en)
|
2000-08-01 |
2002-02-13 |
The Johns Hokpins University |
Intercellular transport protein linked to an antigen as a molecular vaccine
|
|
AU2001278117A1
(en)
*
|
2000-08-03 |
2002-02-18 |
Johns Hopkins University |
Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
SG137691A1
(en)
|
2000-09-28 |
2007-12-28 |
Chiron Corp |
Microparticles for delivery of the heterologous nucleic acids
|
|
WO2002034771A2
(en)
|
2000-10-27 |
2002-05-02 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
|
US7731975B2
(en)
|
2001-01-31 |
2010-06-08 |
The United States Of America As Represented By The Secretary Of The Army |
Chimeric filovirus glycoprotein
|
|
AU2002242016A1
(en)
|
2001-02-01 |
2002-08-12 |
The Johns Hopkins University |
Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
|
|
WO2002072027A2
(en)
|
2001-03-14 |
2002-09-19 |
University Of Alabama Research Foundation |
Oncolytic rna replicons
|
|
WO2002074920A2
(en)
*
|
2001-03-16 |
2002-09-26 |
Johns Hopkins University |
A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
|
|
CA2445947A1
(en)
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US20030077251A1
(en)
|
2001-05-23 |
2003-04-24 |
Nicolas Escriou |
Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
|
|
EP1903054A3
(de)
|
2001-06-05 |
2008-07-23 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
|
|
JP2005506322A
(ja)
|
2001-08-31 |
2005-03-03 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
|
|
CA2460269C
(en)
|
2001-09-06 |
2013-01-15 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
|
US20050163832A1
(en)
|
2002-02-13 |
2005-07-28 |
Vladimir Torchilin |
Intracellular delivery of therapeutic agents
|
|
DE10207177A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
|
WO2004002453A1
(en)
|
2002-06-28 |
2004-01-08 |
Protiva Biotherapeutics Ltd. |
Method and apparatus for producing liposomes
|
|
AU2003244855A1
(en)
|
2002-07-05 |
2004-01-23 |
Lipoxen Technologies Limited |
Method to enhance an immune response of nucleic acid vaccination
|
|
EP1530585A2
(en)
|
2002-08-22 |
2005-05-18 |
Cytos Biotechnology AG |
Inducible alphaviral/orip based gene expression system
|
|
NZ538719A
(en)
|
2002-09-13 |
2008-05-30 |
Replicor Inc |
Non-sequence complementary antiviral oligonucleotides
|
|
WO2004055166A2
(en)
|
2002-12-13 |
2004-07-01 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
|
PT2311848E
(pt)
|
2002-12-23 |
2013-10-03 |
Vical Inc |
Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
|
|
US8338583B2
(en)
|
2003-02-04 |
2012-12-25 |
Bar-Ilan University |
Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids
|
|
WO2004076645A2
(en)
|
2003-02-27 |
2004-09-10 |
University Of Massachusetts |
Compositions and methods for cytomegalovirus treatment
|
|
US7442381B2
(en)
|
2003-03-20 |
2008-10-28 |
Alphavax, Inc. |
Alphavirus replicons and helper constructs
|
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
|
WO2004105774A1
(ja)
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
|
|
MXPA05013260A
(es)
|
2003-06-26 |
2006-03-09 |
Chiron Corp |
Composiciones inmunogenicas para chlamydia trachomatis.
|
|
AU2004257214B2
(en)
|
2003-07-11 |
2010-04-22 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
|
US7368537B2
(en)
*
|
2003-07-15 |
2008-05-06 |
Id Biomedical Corporation Of Quebec |
Subunit vaccine against respiratory syncytial virus infection
|
|
SG190613A1
(en)
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
|
PT1648500E
(pt)
|
2003-07-31 |
2014-10-10 |
Novartis Vaccines & Diagnostic |
Composições imunogénicas para estreptococos piogenes
|
|
EP1512393A1
(de)
|
2003-09-08 |
2005-03-09 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
|
|
US20050208020A1
(en)
|
2003-11-12 |
2005-09-22 |
Doolan Denise L |
Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
|
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
PT1751289E
(pt)
|
2004-05-18 |
2009-03-31 |
Alphavax Inc |
Vectores de alfavirais derivados da tc-83, partículas e métodos
|
|
CA2566355C
(en)
|
2004-05-18 |
2014-04-15 |
Vical Incorporated |
Influenza virus vaccine composition and methods of use
|
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
|
AU2005251403B2
(en)
*
|
2004-06-07 |
2011-09-01 |
Arbutus Biopharma Corporation |
Cationic lipids and methods of use
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
EP1773403B1
(en)
|
2004-07-09 |
2018-04-25 |
The University of North Carolina At Chapel Hill |
Alphavirus-based adjuvants
|
|
WO2006007712A1
(en)
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
|
US20080311158A1
(en)
|
2004-10-01 |
2008-12-18 |
Marcello Merola |
Hepatitis C Virus Replication System
|
|
CA2587337A1
(en)
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
|
GB2421025A
(en)
|
2004-12-09 |
2006-06-14 |
Oxxon Therapeutics Ltd |
HSV vaccination vectors
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
WO2007086881A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
AU2006216844B2
(en)
|
2005-02-18 |
2012-11-08 |
Novartis Vaccines And Diagnostics S.R.L. |
Immunogens from uropathogenic escherichia coli
|
|
EP1858920B1
(en)
|
2005-02-18 |
2016-02-03 |
GlaxoSmithKline Biologicals SA |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
DE602006008278D1
(de)
|
2005-03-02 |
2009-09-17 |
|
Pharmazeutische zusammensetzung
|
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
NZ591415A
(en)
|
2005-03-30 |
2012-10-26 |
Novartis Vaccines & Diagnostic |
Haemophilus influenzae type B
|
|
US7618393B2
(en)
|
2005-05-03 |
2009-11-17 |
Pharmajet, Inc. |
Needle-less injector and method of fluid delivery
|
|
EP1891096A2
(en)
|
2005-05-12 |
2008-02-27 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for chlamydia trachomatis
|
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
|
WO2007014754A1
(en)
|
2005-08-02 |
2007-02-08 |
I.D.M. Immuno-Designed Molecules |
Process for the preparation of liposomal formulations
|
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
|
EP1764089A1
(en)
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
JP5101512B2
(ja)
|
2005-09-29 |
2012-12-19 |
エラン ファーマシューティカルズ，インコーポレイテッド |
Ｖｌａ−４によって媒介される白血球接着を阻害するピリミジニルアミド化合物
|
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
|
JP2007112768A
(ja)
|
2005-10-24 |
2007-05-10 |
Kyoto Univ |
肝指向性リポソーム組成物
|
|
CA2627302A1
(en)
|
2005-10-25 |
2007-05-03 |
Novartis Vaccines And Diagnostics S.R.L. |
Compositions comprising yersinia pestis antigens
|
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
|
ES2564241T3
(es)
|
2005-12-02 |
2016-03-21 |
Glaxosmithkline Biologicals Sa |
Nanopartículas para su uso en composiciones inmunogénicas
|
|
EP2004141A2
(en)
|
2006-03-17 |
2008-12-24 |
Novosom AG |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
|
EP2037959B1
(en)
|
2006-06-07 |
2016-01-27 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
DK2035581T3
(da)
|
2006-06-21 |
2012-10-08 |
Scripps Research Inst |
Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf
|
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
|
WO2008033966A2
(en)
|
2006-09-12 |
2008-03-20 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
EP2131848A4
(en)
|
2007-02-16 |
2012-06-27 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES
|
|
US20100196492A1
(en)
|
2007-03-08 |
2010-08-05 |
Green Jordan J |
Electrostatic coating of particles for drug delivery
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
|
EP2157982B1
(en)
|
2007-05-04 |
2014-12-17 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
|
WO2008148068A1
(en)
|
2007-05-23 |
2008-12-04 |
Mannkind Corporation |
Multicistronic vectors and methods for their design
|
|
DE102007029471A1
(de)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
Neue fakultativ kationische Sterole
|
|
US7850977B2
(en)
|
2007-06-21 |
2010-12-14 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
|
WO2009003975A1
(en)
|
2007-07-04 |
2009-01-08 |
Ribovax Biotechnologies Sa |
Antibodies against human cytomegalovirus (hcmv)
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
US20110177155A1
(en)
|
2007-08-21 |
2011-07-21 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
|
GB0717187D0
(en)
|
2007-09-04 |
2007-10-17 |
Novartis Ag |
Compositions comprising yersinia pestis antigens
|
|
EP2205751A2
(en)
|
2007-09-26 |
2010-07-14 |
Vanderbilt University |
Vaccine for rsv and mpv
|
|
EP2042193A1
(en)
*
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA Vaccines
|
|
AU2008338803B2
(en)
|
2007-11-26 |
2015-02-05 |
Glaxosmithkline Biologicals S.A. |
Methods of generating alphavirus particles
|
|
EP2067749A1
(en)
|
2007-11-29 |
2009-06-10 |
Total Petrochemicals France |
Process for purification of an aqueous phase containing polyaromatics
|
|
WO2009074861A2
(en)
|
2007-12-10 |
2009-06-18 |
Powderject Research Limited |
Improved vaccine
|
|
CA3044134A1
(en)
|
2008-01-02 |
2009-07-09 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
US20110165223A1
(en)
|
2008-01-02 |
2011-07-07 |
The Johns Hopkins University |
Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
|
|
ITMI20081249A1
(it)
|
2008-07-09 |
2010-01-09 |
Novartis Vaccines & Diagnostic |
Immunogeni di escherichia coli con solubilità migliorata.
|
|
WO2009109860A2
(en)
|
2008-03-06 |
2009-09-11 |
Novartis Ag |
Mutant forms of chlamydia htra
|
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
|
US20100040650A1
(en)
|
2008-05-30 |
2010-02-18 |
Crowe Jr James E |
Virus-Like paramyxovirus particles and vaccines
|
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
|
WO2009156155A1
(en)
|
2008-06-25 |
2009-12-30 |
Probiogen Ag |
Cell line for propagation of highly attenuated alphaviruses
|
|
CA2729248A1
(en)
|
2008-06-25 |
2009-12-30 |
Novartis Ag |
Rapid responses to delayed booster immunisations
|
|
CN102203133B
(zh)
|
2008-07-16 |
2015-01-07 |
生物医学研究学会 |
人巨细胞病毒中和抗体及其应用
|
|
KR20150002895A
(ko)
|
2008-07-16 |
2015-01-07 |
인스티튜트 포 리서치 인 바이오메드슨 |
인간 사이토메갈바이러스 중화 항체 및 이의 용도
|
|
JP2010025644A
(ja)
|
2008-07-16 |
2010-02-04 |
Kochi Univ Of Technology |
硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法
|
|
EP2328614A1
(en)
|
2008-08-06 |
2011-06-08 |
Novartis AG |
Microparticles for use in immunogenic compositions
|
|
CL2008002322A1
(es)
|
2008-08-07 |
2009-06-05 |
Univ Concepcion |
Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
|
|
WO2010019718A2
(en)
|
2008-08-13 |
2010-02-18 |
California Institute Of Technology |
Carrier nanoparticles and related compositions, methods and systems
|
|
WO2010036948A2
(en)
|
2008-09-26 |
2010-04-01 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Dna prime/inactivated vaccine boost immunization to influenza virus
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
MX2011004859A
(es)
|
2008-11-07 |
2011-08-03 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
JP5832898B2
(ja)
|
2008-11-10 |
2015-12-16 |
テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ |
治療薬を送達するための新規な脂質及び組成物
|
|
AU2009316680B2
(en)
|
2008-11-18 |
2016-03-24 |
Takeda Vaccines, Inc. |
RSV F VLPs and methods of manufacture and use thereof
|
|
CA2751342C
(en)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
|
RU2508126C2
(ru)
|
2009-04-14 |
2014-02-27 |
Новартис Аг |
Композиции для иммунизации против staphylococcus aureus
|
|
EP3504967A1
(en)
|
2009-05-05 |
2019-07-03 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
|
SG10201912450XA
(en)
|
2009-06-10 |
2020-03-30 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
WO2011001780A1
(ja)
|
2009-07-02 |
2011-01-06 |
コニカミノルタホールディングス株式会社 |
特定分散剤を含有する外水相を利用する二段階乳化法によるリポソームの製造方法、ならびに当該リポソームの製造方法を用いるリポソーム分散液またはその乾燥粉末の製造方法およびそれにより製造されるリポソーム分散液またはその乾燥粉末
|
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
WO2011008974A2
(en)
|
2009-07-15 |
2011-01-20 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
|
US9642903B2
(en)
*
|
2009-07-16 |
2017-05-09 |
Lior Carmon |
Antigen specific multi epitope-based anti-infective vaccines
|
|
KR20140119197A
(ko)
|
2009-07-31 |
2014-10-08 |
에트리스 게엠베하 |
단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 ｒｎａ
|
|
NZ598654A
(en)
|
2009-09-02 |
2014-05-30 |
Novartis Ag |
Immunogenic compositions including tlr activity modulators
|
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
US20110070260A1
(en)
|
2009-09-09 |
2011-03-24 |
Baric Ralph S |
Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
US20110112353A1
(en)
|
2009-11-09 |
2011-05-12 |
Circulite, Inc. |
Bifurcated outflow cannulae
|
|
NZ700688A
(en)
|
2009-12-01 |
2016-02-26 |
Shire Human Genetic Therapies |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
US8808982B2
(en)
|
2009-12-07 |
2014-08-19 |
Cellscript, Llc |
Compositions and methods for reprogramming eukaryotic cells
|
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
CN102905763B
(zh)
|
2009-12-23 |
2015-06-17 |
诺华股份有限公司 |
脂质、脂质组合物和使用它们的方法
|
|
CA2787598A1
(en)
|
2010-01-24 |
2012-06-21 |
Novartis Ag |
Irradiated biodegradable polymer microparticles
|
|
ES2651005T3
(es)
|
2010-03-09 |
2018-01-23 |
Biomedical Research Models, Inc. |
Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2
|
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスｂ１９のウイルス様粒子を生成するための方法
|
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
|
PT2590626E
(pt)
*
|
2010-07-06 |
2016-01-26 |
Glaxosmithkline Biolog Sa |
Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
|
|
AU2011276236B2
(en)
|
2010-07-06 |
2016-03-10 |
Glaxosmithkline Biologicals S.A. |
Cationic oil-in-water emulsions
|
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
US8898852B2
(en)
|
2010-08-04 |
2014-12-02 |
Honeywell International Inc. |
Air burst to clear detection window
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2577983C2
(ru)
|
2010-08-31 |
2016-03-20 |
Новартис Аг |
Липиды, подходящие для липосомной доставки кодирующей белок рнк
|
|
EP2611467B1
(en)
|
2010-08-31 |
2022-07-20 |
GlaxoSmithKline Biologicals SA |
Small liposomes for delivery of immunogen-encoding rna
|
|
HUE058361T2
(hu)
|
2010-08-31 |
2022-07-28 |
Glaxosmithkline Biologicals Sa |
Pegilált liposzómák immunogént kódoló RNA bejuttatására
|
|
US20130164289A1
(en)
|
2010-09-09 |
2013-06-27 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
|
EP4108671B1
(en)
|
2010-10-01 |
2024-11-20 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
ES2945135T3
(es)
|
2010-10-11 |
2023-06-28 |
Glaxosmithkline Biologicals Sa |
Plataformas de suministro de antígenos
|
|
AR083548A1
(es)
|
2010-10-25 |
2013-03-06 |
Stepan Co |
Composiciones de amonio cuaternario, betaina, o sulfobetainas
|
|
US10342862B2
(en)
|
2011-01-26 |
2019-07-09 |
Glaxosmithkline Biologicals, Sa |
RSV immunization regimen
|
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
|
PL3275892T3
(pl)
|
2011-05-13 |
2020-09-07 |
Glaxosmithkline Biologicals S.A. |
Przedfuzyjne antygeny RSV F
|
|
AU2012255913A1
(en)
|
2011-05-17 |
2013-11-21 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
EP3336082B1
(en)
|
2011-06-08 |
2020-04-15 |
Translate Bio, Inc. |
Cleavable lipids
|
|
ES2861428T3
(es)
|
2011-07-06 |
2021-10-06 |
Glaxosmithkline Biologicals Sa |
Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
CN103796639B
(zh)
|
2011-07-06 |
2017-05-31 |
诺华股份有限公司 |
阳离子水包油乳液
|
|
EP2729125B1
(en)
|
2011-07-06 |
2017-12-13 |
GlaxoSmithKline Biologicals SA |
Oil-in-water emulsions that contain nucleic acids
|
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
JP2014525461A
(ja)
|
2011-08-31 |
2014-09-29 |
ノバルティス アーゲー |
免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
|
|
WO2013039861A2
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
ES2911677T3
(es)
|
2011-10-03 |
2022-05-20 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
|
|
CN104105504A
(zh)
|
2011-10-11 |
2014-10-15 |
诺华股份有限公司 |
重组多顺反子核酸分子
|
|
US20140348863A1
(en)
|
2011-10-12 |
2014-11-27 |
Alessia Bianchi |
Cmv antigens and uses thereof
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
MX2014007233A
(es)
|
2011-12-16 |
2015-02-04 |
Moderna Therapeutics Inc |
Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
|
|
EP2793906A4
(en)
|
2011-12-21 |
2016-01-13 |
Moderna Therapeutics Inc |
METHOD FOR INCREASING THE LIFE-LIFE OR DURABILITY OF AN ORGAN OR ORGAN EXPLOITATE
|
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
RU2015132962A
(ru)
|
2013-01-10 |
2017-02-14 |
Новартис Аг |
Иммуногенные композиции на основе вируса гриппа и их применение
|
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2895651T3
(es)
|
2013-12-19 |
2022-02-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
WO2017049245A2
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
PL3368507T3
(pl)
|
2015-10-28 |
2023-03-27 |
Acuitas Therapeutics Inc. |
Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych
|
|
WO2018089790A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Improved ice-based lipid nanoparticle formulation for delivery of mrna
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
EP3883592A1
(en)
|
2018-11-21 |
2021-09-29 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
WO2021038508A1
(en)
|
2019-08-30 |
2021-03-04 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|